← Brewed Up Insight No. 66

NPPA's cap would cut a ₹270 cancer drug to ₹143

What a patient pays for a cancer drug its maker sells at ₹100, today and with NPPA's cap. The maker's ₹100 stays; the supply chain's share shrinks.

NPPA's cap would cut a ₹270 cancer drug to ₹143

What a patient pays for a cancer drug its maker sells at ₹100, today and with NPPA's cap. The maker's ₹100 stays; the supply chain's share shrinks.

Stream chart of what a patient pays for a cancer drug its maker sells at ₹100. Today, with the average trade mark-up of 170%, the patient pays ₹270: ₹100 to the maker and ₹170 to distributors, chemists and hospital pharmacies. With NPPA's cap of a 30% trade margin on MRP, the patient pays ₹143: the maker's ₹100 and ₹43 for the supply chain. The example assumes the mark-up is counted from the maker's price; NPPA expects MRPs to fall 20% to 70%.

₹ A PATIENT PAYS FOR A DRUG ITS MAKER SELLS AT ₹100

Maker's priceTrade margin

Trade margin: what distributors, chemists and hospital pharmacies add to the maker's price. The example assumes the 170% average mark-up is counted from the maker's price. NPPA expects MRPs to fall 20% to 70%, depending on each drug's mark-up today.

NPPA, minutes of the 151st Authority meeting, 8 October 2026; worked example · Oct 2026

Share it

The numbers

Embed it on your site

The code carries a credit line that links back to this page. Keep it with the chart.

Get in touch